FI110609B - Förfarande för framställning av tillväxthormonkristaller - Google Patents
Förfarande för framställning av tillväxthormonkristaller Download PDFInfo
- Publication number
- FI110609B FI110609B FI952021A FI952021A FI110609B FI 110609 B FI110609 B FI 110609B FI 952021 A FI952021 A FI 952021A FI 952021 A FI952021 A FI 952021A FI 110609 B FI110609 B FI 110609B
- Authority
- FI
- Finland
- Prior art keywords
- crystals
- growth hormone
- hgh
- buffer
- phenyl
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 94
- 102000018997 Growth Hormone Human genes 0.000 title claims abstract description 59
- 108010051696 Growth Hormone Proteins 0.000 title claims abstract description 59
- 239000000122 growth hormone Substances 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title description 12
- 239000000872 buffer Substances 0.000 claims abstract description 18
- 150000001875 compounds Chemical class 0.000 claims abstract description 11
- 125000001624 naphthyl group Chemical class 0.000 claims abstract description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 6
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 5
- 239000007864 aqueous solution Substances 0.000 claims abstract description 4
- 238000002156 mixing Methods 0.000 claims abstract description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 36
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 12
- XPNGNIFUDRPBFJ-UHFFFAOYSA-N (2-methylphenyl)methanol Chemical compound CC1=CC=CC=C1CO XPNGNIFUDRPBFJ-UHFFFAOYSA-N 0.000 claims description 6
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims description 6
- VAJVDSVGBWFCLW-UHFFFAOYSA-N 3-Phenyl-1-propanol Chemical compound OCCCC1=CC=CC=C1 VAJVDSVGBWFCLW-UHFFFAOYSA-N 0.000 claims description 6
- CDRQOYRPWJULJN-UHFFFAOYSA-N 1-naphthalen-1-ylethanol Chemical compound C1=CC=C2C(C(O)C)=CC=CC2=C1 CDRQOYRPWJULJN-UHFFFAOYSA-N 0.000 claims description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N 1-propanol Substances CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
- BDCFWIDZNLCTMF-UHFFFAOYSA-N 2-phenylpropan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1 BDCFWIDZNLCTMF-UHFFFAOYSA-N 0.000 claims description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 2
- 101001075374 Homo sapiens Gamma-glutamyl hydrolase Proteins 0.000 claims 2
- 101000664737 Homo sapiens Somatotropin Proteins 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 108010000521 Human Growth Hormone Proteins 0.000 description 38
- 102000002265 Human Growth Hormone Human genes 0.000 description 38
- 239000000854 Human Growth Hormone Substances 0.000 description 38
- 239000000203 mixture Substances 0.000 description 23
- 239000000243 solution Substances 0.000 description 17
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 16
- 238000009472 formulation Methods 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 238000003860 storage Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 9
- 229930195725 Mannitol Natural products 0.000 description 9
- 239000000594 mannitol Substances 0.000 description 9
- 235000010355 mannitol Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 239000004471 Glycine Substances 0.000 description 8
- 150000001768 cations Chemical class 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 108010006025 bovine growth hormone Proteins 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropanol Chemical compound CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- -1 1% acetic acid Chemical class 0.000 description 2
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 2
- JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000012537 formulation buffer Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229940063135 genotropin Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000003547 immunosorbent Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- SQYNKIJPMDEDEG-UHFFFAOYSA-N paraldehyde Chemical compound CC1OC(C)OC(C)O1 SQYNKIJPMDEDEG-UHFFFAOYSA-N 0.000 description 2
- 229960003868 paraldehyde Drugs 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- HQRWWHIETAKIMO-JTQLQIEISA-N (1s)-1-phenylbutan-1-ol Chemical compound CCC[C@H](O)C1=CC=CC=C1 HQRWWHIETAKIMO-JTQLQIEISA-N 0.000 description 1
- BWRBVBFLFQKBPT-UHFFFAOYSA-N (2-nitrophenyl)methanol Chemical compound OCC1=CC=CC=C1[N+]([O-])=O BWRBVBFLFQKBPT-UHFFFAOYSA-N 0.000 description 1
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- IJXJGQCXFSSHNL-MRVPVSSYSA-N (2s)-2-amino-2-phenylethanol Chemical compound OC[C@@H](N)C1=CC=CC=C1 IJXJGQCXFSSHNL-MRVPVSSYSA-N 0.000 description 1
- KOVQGYQQVNCUBR-UHFFFAOYSA-N (3-methyl-4-nitrophenyl)methanol Chemical compound CC1=CC(CO)=CC=C1[N+]([O-])=O KOVQGYQQVNCUBR-UHFFFAOYSA-N 0.000 description 1
- WAPNOHKVXSQRPX-UHFFFAOYSA-N 1-phenylethanol Chemical compound CC(O)C1=CC=CC=C1 WAPNOHKVXSQRPX-UHFFFAOYSA-N 0.000 description 1
- 101150055869 25 gene Proteins 0.000 description 1
- JKTYGPATCNUWKN-UHFFFAOYSA-N 4-nitrobenzyl alcohol Chemical compound OCC1=CC=C([N+]([O-])=O)C=C1 JKTYGPATCNUWKN-UHFFFAOYSA-N 0.000 description 1
- 101100335894 Caenorhabditis elegans gly-8 gene Proteins 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- 206010021067 Hypopituitarism Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 101100285000 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) his-3 gene Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 101710128967 Somatotropin-1 Proteins 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 101150006914 TRP1 gene Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229950011260 betanaphthol Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 229940075397 calomel Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- ZOMNIUBKTOKEHS-UHFFFAOYSA-L dimercury dichloride Chemical compound Cl[Hg][Hg]Cl ZOMNIUBKTOKEHS-UHFFFAOYSA-L 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229960004532 somatropin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical class [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000007794 visualization technique Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (5)
1. Förfarande för att tillverka kristaller av tillväxthor-mon (GH) eller funktionella derivat därav, kännetecknat av 5 stegen: i) att blanda GH eller funktionella derivat därav med en vattenhaltiglösning som innefattar en buffert och en kemisk förening med den allmänna formeln (I): 10 Ar- [ -CR.R„- ] - [-C R,R-] - C R,R-OH (I) i vilken Ar är fenyl, alkylsubstituerad fenyl, naftyl, alkylsubstitu-15 erad naftyl, R. till R- är H, OH eller alkyl, n och m är 0 eller 1, ii) att inkubera, iii) att isolera kristallerna med kända metoder. 20
2. Förfarande enligt patentkrav 1, kännetecknat av att GH är humant GH.
3. Förfarande enligt patentkrav 2, kännetecknat av att GH 25 är rekombinant humant GH(rhGH).
, 4. Förfarande enligt nägot av patentkraven 1-3, känneteck- • I V nat av att föreningen väljs bland bensylalkohol, 2- metylbensylalkohol, 1-(1-naftyl)etanol, fenyletanol, Ι- ΙΟ felnyl-1-propanol, 2-fenyl-2-propanol, 3-fenyl-l-propanol.
5. Förfarande enligt patentkrav 4, kännetecknat av att fö-,·" reningen är bensylalkohol. I > t I » » < t • ♦ I f > · |Mt
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9203175A SE9203175D0 (sv) | 1992-10-28 | 1992-10-28 | Growth hormone |
| SE9203175 | 1992-10-28 | ||
| SE19939302278A SE9302278D0 (sv) | 1992-10-28 | 1993-07-02 | Growth hormone |
| SE9302278 | 1993-07-02 | ||
| PCT/SE1993/000885 WO1994010192A1 (en) | 1992-10-28 | 1993-10-27 | Process for manufacturing crystals of growth hormone and crystals thereby obtained |
| SE9300885 | 1993-10-27 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI952021A0 FI952021A0 (sv) | 1995-04-27 |
| FI952021A FI952021A (sv) | 1995-04-27 |
| FI110609B true FI110609B (sv) | 2003-02-28 |
Family
ID=26661557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI952021A FI110609B (sv) | 1992-10-28 | 1995-04-27 | Förfarande för framställning av tillväxthormonkristaller |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5734026A (sv) |
| EP (1) | EP0669934B1 (sv) |
| JP (1) | JP3470135B2 (sv) |
| AT (1) | ATE174602T1 (sv) |
| AU (1) | AU679012B2 (sv) |
| CA (1) | CA2147482C (sv) |
| DE (1) | DE69322654T2 (sv) |
| DK (1) | DK0669934T3 (sv) |
| ES (1) | ES2126660T3 (sv) |
| FI (1) | FI110609B (sv) |
| HK (1) | HK1013299A1 (sv) |
| NO (1) | NO320171B1 (sv) |
| SE (1) | SE9302278D0 (sv) |
| WO (1) | WO1994010192A1 (sv) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9302278D0 (sv) * | 1992-10-28 | 1993-07-02 | Kabi Pharmacia Ab | Growth hormone |
| EP1009759B1 (en) | 1997-09-05 | 2008-05-28 | Altus Pharmaceuticals Inc. | Carbohydrate crosslinked glycoprotein crystals |
| US6500933B1 (en) | 1997-09-05 | 2002-12-31 | Altus Biologics Inc. | Methods of preparing carbohydrate crosslinked glycoprotein crystals |
| US6380357B2 (en) | 1997-12-16 | 2002-04-30 | Eli Lilly And Company | Glucagon-like peptide-1 crystals |
| US6541606B2 (en) * | 1997-12-31 | 2003-04-01 | Altus Biologics Inc. | Stabilized protein crystals formulations containing them and methods of making them |
| US20050148497A1 (en) * | 2002-02-20 | 2005-07-07 | Khan Mohammed A. | Method for administering glp-1 molecules |
| SE0202719D0 (sv) * | 2002-09-13 | 2002-09-13 | Pharmacia Ab | Process for mfg crystals of growth hormone |
| EP2460530A3 (en) | 2002-12-31 | 2012-08-29 | Althea Technologies, Inc. | Human growth hormone crystals and methods for preparing them |
| US20060286129A1 (en) * | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
| US7444197B2 (en) | 2004-05-06 | 2008-10-28 | Smp Logic Systems Llc | Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes |
| US7799273B2 (en) | 2004-05-06 | 2010-09-21 | Smp Logic Systems Llc | Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes |
| EP1976551A4 (en) * | 2005-12-23 | 2009-12-30 | Altus Pharmaceuticals Inc | COMPOSITIONS COMPRISING COMPLEX PROTEIN CRYSTALS BY POLYCATIONS AND PROCESSING METHOD THEREOF |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY107450A (en) * | 1990-06-04 | 1995-12-30 | Schering Corp | Method for preparing interferon alpha-2 crystals. |
| PL166951B1 (pl) * | 1990-06-15 | 1995-07-31 | Schering Corp | Sposób wytwarzania tetragonalnych krysztalów ludzkiej interleukiny-4 PL PL PL PL |
| DK168790D0 (sv) * | 1990-07-13 | 1990-07-13 | Novo Nordisk As | |
| US5015627A (en) * | 1990-07-20 | 1991-05-14 | Smithkline Beecham Corporation | Stabilized somatotropin for parenteral administration |
| SE9302278D0 (sv) * | 1992-10-28 | 1993-07-02 | Kabi Pharmacia Ab | Growth hormone |
-
1993
- 1993-07-02 SE SE19939302278A patent/SE9302278D0/sv unknown
- 1993-10-27 DK DK93924266T patent/DK0669934T3/da active
- 1993-10-27 CA CA002147482A patent/CA2147482C/en not_active Expired - Fee Related
- 1993-10-27 AU AU54011/94A patent/AU679012B2/en not_active Ceased
- 1993-10-27 EP EP93924266A patent/EP0669934B1/en not_active Expired - Lifetime
- 1993-10-27 ES ES93924266T patent/ES2126660T3/es not_active Expired - Lifetime
- 1993-10-27 DE DE69322654T patent/DE69322654T2/de not_active Expired - Fee Related
- 1993-10-27 JP JP51096494A patent/JP3470135B2/ja not_active Expired - Fee Related
- 1993-10-27 AT AT93924266T patent/ATE174602T1/de not_active IP Right Cessation
- 1993-10-27 WO PCT/SE1993/000885 patent/WO1994010192A1/en active IP Right Grant
- 1993-10-27 US US08/424,450 patent/US5734026A/en not_active Expired - Fee Related
-
1995
- 1995-04-24 NO NO19951547A patent/NO320171B1/no unknown
- 1995-04-27 FI FI952021A patent/FI110609B/sv active
-
1998
- 1998-12-22 HK HK98114660A patent/HK1013299A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NO951547D0 (no) | 1995-04-24 |
| JPH08505127A (ja) | 1996-06-04 |
| FI952021A0 (sv) | 1995-04-27 |
| ES2126660T3 (es) | 1999-04-01 |
| US5734026A (en) | 1998-03-31 |
| DE69322654D1 (de) | 1999-01-28 |
| HK1013299A1 (en) | 1999-08-20 |
| CA2147482A1 (en) | 1994-05-11 |
| WO1994010192A1 (en) | 1994-05-11 |
| DE69322654T2 (de) | 1999-06-17 |
| FI952021A (sv) | 1995-04-27 |
| SE9302278D0 (sv) | 1993-07-02 |
| ATE174602T1 (de) | 1999-01-15 |
| AU679012B2 (en) | 1997-06-19 |
| EP0669934B1 (en) | 1998-12-16 |
| NO951547L (no) | 1995-04-24 |
| DK0669934T3 (da) | 1999-08-23 |
| AU5401194A (en) | 1994-05-24 |
| EP0669934A1 (en) | 1995-09-06 |
| CA2147482C (en) | 2003-09-23 |
| JP3470135B2 (ja) | 2003-11-25 |
| NO320171B1 (no) | 2005-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI110609B (sv) | Förfarande för framställning av tillväxthormonkristaller | |
| Lowry et al. | Properties of a simplified bioassay for adrenocorticotrophic activity using the steroidogenic response of isolated adrenal cells | |
| EP0367590B1 (en) | Augmenting fetal hemoglobin by treatment with activin and/or inhibin | |
| US5216004A (en) | Method for preventing malaria | |
| JP4482267B2 (ja) | 接合安定化されたポリペプチド組成物 | |
| US5919757A (en) | Aqueous pharmaceutical preparations of G-CSF with a long shelf life | |
| FI66751B (fi) | Foerfarande foer framstaellning av ett stabilt insulinpreparatmed laongtidsverkan | |
| EP0548276A1 (en) | Method for increasing red blood cell production by treatment with activin or activin-related peptides | |
| KR20080071192A (ko) | 면역글로불린 융합 단백질 제형 | |
| AU638474B2 (en) | Surfactant compositions and methods | |
| KR20010041152A (ko) | 리포솜성 에리트로포이에틴 분산액 | |
| US5898030A (en) | hGH containing pharmaceutical compositions | |
| CZ20031401A3 (cs) | Repinotanová souprava | |
| CA2063273C (en) | Surfactant compositions and methods | |
| KR20040018458A (ko) | Ｃｅｔｕｘｉｍａｂ 및 폴리옥시에틸렌 소르비탄 지방산에스테르를 포함하는 액형 제제 | |
| WO1996033216A1 (en) | Truncated igf-i | |
| AU730367B2 (en) | Water-soluble peptides | |
| KR100548107B1 (ko) | 뼈 유도 인자 인간 ｍｐ52 동결 건조 조성물 | |
| EP0397409A1 (en) | The stabilization of organic compounds | |
| JPH0249734A (ja) | 新規組成物 | |
| WO1995002411A1 (en) | Stabilised polypeptide growth factor formulation at low ph | |
| WO2024009205A1 (en) | STABLE LIQUID FORMULATION OF AN ANTI-Α4ß7 ANTIBODY | |
| CA3234358A1 (en) | Stable lyophilized formulation of an anti-.alpha.4.beta.7 antibody | |
| EA022617B1 (ru) | Монопегилированный интерферон-альфа разветвленной структуры и фармацевтическая композиция для приготовления лекарственного средства, обладающего активностью интерферона-альфа |